Similarly, stimulating CAR T cells with IL-2 and GM-CSF has been shown to induce CXCR3 expression on CAR T cells, leading to enhanced infiltration into hepatocellular carcinoma [49], suggesting that this strategy can lead to improvements in CAR T cells immunotherapy for GBM (Table 3). The gene discussed is CXCR3; the disease is glioblastoma.